Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
TASP0415914
Cat. No.:
0225LY-1492
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
TASP0415914 is a potent, orally available inhibitor designed to target phosphoinositide 3-kinase γ.
Synonym:
1292300-75-4; N-(5-(3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl)-4-methylthiazol-2-yl)acetamide; N-[5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl]acetamide
CAS No.:
1292300-75-4
Compound CID:
72737552
Formula:
C13H17N5O3S
Formula Weight:
323.37
Specification
Targets&IC50:
Akt: 294 nM (IC50); PI3Kγ: 29 nM (IC50)
Relative Density:
1.435 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
TASP0415914 can be used in oncology research to investigate the selective inhibition of PI3K beta and its impact on PTEN-deficient tumors.
Library Information
Target:
Akt; PI3K
Receptor:
Akt; PI3Kγ
Pathways:
Cytoskeletal signaling; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-20
Plate Location:
b5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
11 mg/mL; 34.02 mM
